Vivo Capital

Activity in this selectionoxford-innovation-finance-03f5fb23

By stage

Series B3

Undisclosed2

Biotech5

United States3

China2

5 in this selection

Jun 10

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B

Role not disclosed

May 18

Clinical-stage radiotherapeutics company developing targeted cancer therapies with integrated isotope manufacturing

$150MSeries D+Debt

Role not disclosed

Apr 9

Develops next-generation cell therapies for oncology and immunology

$110MPre-IPO

Role not disclosed

Jan 10

Develops inhaled therapies for severe respiratory diseases

$103MSeries B

Role not disclosed

Jan 8

Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...

$107MSeries B

Role not disclosed